In the largest U.S. study of venom allergy and mastocytosis prevalence, Michigan Medicine researchers found that people with venom allergy are nearly 10 times more likely to suffer the bone marrow disorder that causes higher risk of fatal reactions. They also found that elevated levels of tryptase, a chemical secreted by allergy cells, may predict if a person is at higher risk for reaction to immunotherapy.
For patients who receive a heart transplant in the near future, the old adage, “Good things come in small packages,” may become words to live by. In a recent study, researchers at Johns Hopkins Medicine and the National Cancer Institute (NCI) demonstrated in mice that they can easily deliver a promising anti-rejection drug directly to the area surrounding a grafted heart by packaging it within a tiny three-dimensional, protein gel cocoon known as a hydrogel. Best of all, the researchers say that the release of the drug is spread out over time, making it highly regulatable and eliminating the need for daily medication to keep rejection in check.